Primary Sclerosing Cholangitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Primary Sclerosing Cholangitis – Drugs In Development, 2024 report and make more profitable business decisions.
Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness, and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.
The Primary Sclerosing Cholangitis drugs in development market research report provide comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Primary Sclerosing Cholangitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 42 molecules, with 41 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Primary Sclerosing Cholangitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Primary Sclerosing Cholangitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Primary Sclerosing Cholangitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAlfasigma SpA
Avolynt Inc
Cascade Pharmaceuticals Inc
Centre for Drug Design and Discovery
Chemomab Therapeutics Ltd
CymaBay Therapeutics Inc
Dr. Falk Pharma GmbH
Emergent Biotechnologies LLC
Engitix Ltd
Galmed Pharmaceuticals Ltd
GRI Bio Inc
Halo Biosciences Inc
Hanmi Pharmaceuticals Co Ltd
HighTide Therapeutics Inc
Iltoo Pharma
Invea Therapeutics Inc
Ipsen SA
LISCure Biosciences Co Ltd
Mirum Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Orbsen Therapeutics Ltd
Parvus Therapeutics Inc
Pliant Therapeutics Inc
ProQR Therapeutics NV
Qing Bile Therapeutics Inc
Scohia Pharma Inc
Shanghai Henlius Biotech Inc
Sirnaomics Ltd
SteroTherapeutics LLC
Takeda Pharmaceutical Co Ltd
Yungjin Pharm Co Ltd
Zydus Lifesciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Primary Sclerosing Cholangitis reports